RFCS Stock Overview
Refocus Group, Inc., a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Refocus Group, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
RFCS | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | -4.4% | -3.7% |
1Y | n/a | -2.8% | 20.2% |
Return vs Industry: Insufficient data to determine how RFCS performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how RFCS performed against the US Market.
Price Volatility
RFCS volatility | |
---|---|
RFCS Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.4% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RFCS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RFCS's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | n/a | Mike Judy | www.refocus-group.com |
Refocus Group, Inc., a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia. The company develops VisAbility Micro-Insert System, an investigational medical device that is in clinical trials for use in the binocular presbyopic treatment. It serves patients and eye care professionals.
Refocus Group, Inc. Fundamentals Summary
RFCS fundamental statistics | |
---|---|
Market cap | US$24.00 |
Earnings (TTM) | -US$4.77m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs RFCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RFCS income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$4.77m |
Earnings | -US$4.77m |
Last Reported Earnings
Sep 30, 2005
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did RFCS perform over the long term?
See historical performance and comparison